Jose Saro

Medicine · Health Sciences

4h-index672citations27works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(25), Radiopharmaceutical Chemistry and Applications(19), Synthesis and Biological Evaluation(10), Advanced Biosensing Techniques and Applications(6), CAR-T cell therapy research(5)

Publications27 total

Supplemental Figure 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Table S2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Figure 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Figure 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Information from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Figure 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Figure 3 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Video 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Figure 3 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Data from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Table S1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Video 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Table S2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Supplemental Information from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Table S1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Data from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Video 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Video 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
Oncotarget·2018· 38 citedOpen Access
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
OncoImmunology·2017· 273 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Marina Bacac(24), Valeria Nicolini(24), Christian Klein(24), Pablo Umaña(24), Tanja Fauti(22), Sara Colombetti(22), Thomas Höfer(22), Ekkehard Moessner(22), Oliver Ast(22), Christian Gerdes(22), Vaios Karanikas(22), Johannes Sam(21), Ralf J. Hosse(21), Peter Bruenker(21), Nathalie Steinhoff(21), Tina Weinzierl(19), Djamila Ouaret(19), Walter F. Bodmer(19), Steffi Lehmann(19), Sandra Grau-Richards(19)